Loading candles…
Healthcare Global Enterprises Ltd operates in the healthcare industry in India, specializing in hospital management, medical diagnostic services, and scientific testing and consultancy within the pharmaceutical and medical sectors. The company focuses primarily on oncology and fertility services and manages the largest oncology-focused hospital network in the country. Its comprehensive cancer care offerings include diagnostics, radiation, medical, and surgical oncology, delivered through a Focused Factory model. Services provided encompass hospital setup and management, medical diagnostics, scientific testing, and consultancy services. There are no publicly listed shares or noted subsidiaries associated with the company.
This page is a live market overview for HEALTHCARE GLOB. ENT. LTD (HCG) on the NSE. As a listed security, HEALTHCARE GLOB. ENT. LTD is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for HCG before placing trades on tick2trade.
As of the latest feed, HCG last traded at ₹675.85 on NSE, down ₹2.65 (0.39%) from the previous close of ₹678.5. Today's session range is ₹656.15 – ₹679.5, against a 52-week band of ₹513.3 – ₹796.68. Traded volume today stands at 3.38L shares.
The overview consolidates an interactive price chart with multiple time ranges, recent market headlines, upcoming corporate events for HCG in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether HCG is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for HEALTHCARE GLOB. ENT. LTD before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in HCG. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated HCG option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Unaudited Results - FY26 | To consider and approve the unaudited financial results for the period ended Jun 30, 2026 and other business matters | 6 Aug 2026 |
| Audited Results - Q4 & FY26 | This is to inform that a meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, May 19, 2026, to consider and approve inter-ali… | 19 May 2026 |
| Intimation | Further to the intimation on the outcome of the meeting of the Board of Directors of the Company ( Board ) held on February 17, 2026 and in compliance with R… | 24 Feb 2026 |
| Other | To consider and approve inter alia, the proposal of fund raise by way of issuance of equity shares through Rights Issue. | 17 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 and other business matters | 5 Feb 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 and other business matters | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 and other business matters | 1 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 and other business matters | 24 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.